ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of September 27, 2023, ALGS stock price declined to $0.71 with 28,479 million shares trading.

ALGS has a beta of 0.84, meaning it tends to be less sensitive to market movements. ALGS has a correlation of 0.03 to the broad based SPY ETF.

ALGS has a market cap of $30.90 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, IWC.

ALGS has underperformed the market in the last year with a price return of -29.0% while the SPY ETF gained +18.7%. ALGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.4% and -11.2%, respectively, while the SPY returned -0.9% and -4.1%, respectively.

ALGS support price is $.70 and resistance is $.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS stock will trade within this expected range on the day.